PHILADELPHIA, Aug. 23, 2011 /PRNewswire/ -- ERT, a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations, announced today the appointment of Linda Deal to lead ERT's Health Outcomes Research initiatives. This strategic appointment extends ERT's commitment to health outcomes research and augments its Patient Reported Outcomes capabilities and multi modality product offering with deeper scientific expertise.
Jeffrey Litwin MD, President and CEO of ERT comments, "Linda's expertise and extensive industry knowledge will assist us in increasingly providing innovative outcomes research solutions to better serve our clients' developing needs. Having worked inside sponsor organizations and across a number of entities within the PRO community, Linda brings insight and perspective on the creation and implementation of Patient, Clinician and Observer reported outcomes. Her domain knowledge will enable her to add considerable value to ERT's offerings and to our clients."
Ms Deal brings a breadth of experience in health outcomes and in the development and validation of patient reported assessments. Most recently she was the Immunology Patient Reported Outcomes (PRO) Lead at Janssen Pharma, a division of Johnson & Johnson, where she was responsible for developing and integrating the PRO strategy within the end to end development process. Prior to Johnson & Johnson, Linda was head of the PRO Center in Global Health Outcomes Assessment (GHOA) at Wyeth Research, now Pfizer. She has also supported health economics and outcomes research for Wyeth, Research Triangle Institute, and Glaxo Welcome.
Over her career, she has designed a number of assessments used in clinical trials today and has prepared over 20 regulatory briefing documents addressing PRO development and validation for supporting registration and labeling. She n